SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (27441)1/18/1999 5:48:00 PM
From: Cacaito  Read Replies (1) | Respond to of 32384
 
Pioglitazone from Takeda-Lilly, to FDA for review. Check prnewswire

Rezulin will get competition.

Is pioglitazone a 1st or 2nd generation?



To: Andrew H who wrote (27441)1/18/1999 6:18:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
LGND still hasn't released the data. I believe that Targretin did act as an insulin sensitizer, but produced elevated triglycerides. LGND then tried to titrate down the concentration, and that's the last that I heard. I thought that data would come out by the end of last year, but it has not happened yet.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News